Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

(NASDAQ:RZLT), Company believes that data from sunRIZE and the Expanded Access Program (EAP) provide evidence of activity of ersodetug in both indications Company plans to meet with FDA to align on path forward for congenital HI REDWOOD CITY, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage […]

New Protocol Mutuum Finance (MUTM) Records 300% Token Growth Since Early 2025 Presale Launch

DUBAI, United Arab Emirates, Jan. 07, 2026 (GLOBE NEWSWIRE) — Mutuum Finance (MUTM) has reported a 300% increase in its token price across Presale stages since the Presale began in early 2025. The project, which is building a decentralized lending and borrowing protocol, says the token has moved from $0.01 in Phase 1 to $0.04

Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline

(NasdaqGM:RAPP), U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarter of 2026 On strength of RAP-219 Phase 2a FOS data, epilepsy portfolio expanded with new program in primary generalized tonic-clonic seizures (PGTCS) Phase 2 trial

BitMart Exchange Announces Partnership with Hit TV-Reality Show CryptoKnights for Season 2

Mahe, Seychelles, Jan. 07, 2026 (GLOBE NEWSWIRE) — BitMart, a trusted global digital asset service provider, today announced its official partnership with CryptoKnights, the world's first reality-TV show centered on blockchain entrepreneurship. Through this landmark collaboration, BitMart CEO Nathan (Nenter) Chow will join Season 2's prestigious judging panel in several episodes of the season, bringing

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

(NasdaqGM:GANX), BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (“JPM week”)

Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects

(NASDAQ:GLUE), In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated rapid and durable reductions in systemic inflammation After four weeks of MRT-8102 treatment, C-reactive protein (CRP) levels were reduced by 85%, and 94% of study participants achieved CRP values

Barrick to Report Full Year and Fourth Quarter 2025 Results on February 5

(TSX:ABX),(NYSE:B),(LSE:0R22), TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Barrick Mining Corporation (NYSE:B)(TSX:ABX) will release its full year and fourth quarter 2025 results before markets open on Thursday, February 5, 2026 at 6:00 AM ET. The management team will host a live webcast and presentation at 11:00 AM ET the same day, followed by a question-and-answer

First Diamond Drill Program Commences at Nobel’s Flagship Cuprita Copper Project, Antofagasta Region, Chile

(TSX-V:NBLC),(OTC US:NBTRF),(Other OTC:NBTRF), TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX – V: NBLC) (the “Company” or “Nobel”) is pleased to announce commencement of mobilization by the Company's diamond drill contractor to the Cuprita copper project (“Cuprita” or the “Project”) and drilling will commence during the week of January 12th. All necessary

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI(R)

(NASDAQ:BTAI), NEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month seeking the U.S. Food and Drug Administration's (FDA) approval of IGALMI(R)

Emerita Intersects 2.1m Grading 1.6% Copper, 0.85 g/t Gold, 32.11 g/t Silver and 1.4m Grading 5.8% Copper, 4.89 g/t Gold and 51.0 g/t Silver at El Cura

(TSX-V:EMO),(OTC US:EMOTF),(Other OTC:EMOTF),(Frankfurt:LLJA), TORONTO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) reports results from ongoing drilling of El Cura deposit. El Cura is part of Emerita's wholly owned Iberian Belt West project (“IBW” or the “Project”; Figure 1) which hosts three Volcanogenic Massive

Scroll to Top